Edition:
United States

Daiichi Sankyo Co Ltd (4568.T)

4568.T on Tokyo Stock Exchange

2,492JPY
21 Jul 2017
Change (% chg)

-- (--)
Prev Close
¥2,492
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,827,371
52-wk High
¥2,670
52-wk Low
¥2,192

4568.T

Chart for 4568.T

About

DAIICHI SANKYO COMPANY, LIMITED is a Japan-based holding company mainly engaged in the manufacture and sale of pharmaceuticals. The Company is involved in the research, development, manufacture and sale of pharmaceuticals, as well as the provision of intermediates and basic materials for pharmaceutical producing in Japan, the... (more)

Overall

Beta: 0.86
Market Cap(Mil.): ¥1,767,211.00
Shares Outstanding(Mil.): 709.01
Dividend: 35.00
Yield (%): 2.81

Financials

  4568.T Industry Sector
P/E (TTM): 31.80 11.79 15.85
EPS (TTM): 78.37 -- --
ROI: 3.05 -10.04 -8.31
ROE: 4.44 -9.89 -7.95

EMA panel recommends against Nektar, Daiichi Sankyo's breast cancer drug

European regulators on Friday recommended against granting approval to a breast cancer drug being developed by Nektar Therapeutics and Daiichi Sankyo's German unit.

Jul 21 2017

EMA panel recommends against Nektar, Daiichi Sankyo's breast cancer drug

July 21 European regulators on Friday recommended against granting approval to a breast cancer drug being developed by Nektar Therapeutics and Daiichi Sankyo's German unit.

Jul 21 2017

BRIEF-Daiichi Sankyo announces top-line results from phase 3 global clinical development program evaluating mirogabalin in pain syndromes

* Daiichi Sankyo announces top-line results from phase 3 global clinical development program evaluating mirogabalin in pain syndromes

Jun 30 2017

BRIEF-Daiichi Sankyo to invest 22 bln yen in U.S. for Luitpold Pharmaceuticals - Nikkei

* Daiichi Sankyo to invest 22 billion yen in U.S. for Luitpold Pharmaceuticals; targets about 70 pct rise in Luitpold's sales to 150 billion yen in fiscal 2020 versus 2015 - Nikkei Source (http://s.nikkei.com/2qhFwVe) Further company coverage:

May 24 2017

BRIEF-Daiichi Sankyo makes 15 bln yen investment

* Daiichi Sankyo - making initial 15 billion yen investment to optimize and enhance manufacturing capabilities to support growing antibody drug conjugate pipeline Source text for Eikon: Further company coverage:

Apr 27 2017

BRIEF-HTG Molecular says entered into master services agreement with Daiichi Sankyo Company

* Htg molecular diagnostics - entered into master services agreement with daiichi sankyo company, ltd for work to be performed in htg's veri/o laboratory

Apr 17 2017

BRIEF-Daiichi Sankyo announces new analyses

* Daiichi Sankyo Inc announces new analyses of once-daily savaysa (edoxaban) in patients with non-valvular atrial fibrillation to be presented at the acc 66th annual scientific session

Mar 13 2017

BRIEF-Sosei Group unit signs alliance for R & D of new small molecule therapeutic drug with DAIICHI SANKYO COMPANY LIMITED.

* Says its subsidiary Heptares signed an alliance for R & D of new small molecule therapeutic drug with DAIICHI SANKYO COMPANY LIMITED. on March 13

Mar 13 2017

BRIEF-EMA recommends approval of Daiichi Sankyo's anticoagulant

* EU Medicines Agency recommends approval Of Daiichi Sankyo's anticoagulant Edoxaban

Feb 24 2017

BRIEF-Daiichi Sankyo and ArQule's carcinoma drug failed in late-stage trial

* Daiichi Sankyo and Arqule announce the completion of the metiv-hcc phase 3 study of tivantinib in second-line treatment of met-overexpressing hepatocellular carcinoma

Feb 17 2017

Earnings vs. Estimates